|
We are building a portfolio of compounds that have first-in-class and best-in-class potential through our own discovery research and clinical development initiatives.
more >
|
 |
03/09/10
Exelixis Announces Fourth Quarter and Full Year 2009 Financial Results
03/08/10
Exelixis Announces Restructuring
|
|
Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference.
more >
One abstract featuring Exelixis' XL184 was presented at the meeting from October 22-24, 2009.
more >
03/10/2010 - 10:15 AM
Exelixis at Cowen and Company Healthcare Conference
|
|
Looking for a career at Exelixis? We are looking for people to join us as we turn our vision into reality.
more >
NASDAQ: EXEL
Mar 10 2010 11:51AM
PRICE: 6.33 +0.02
VOLUME: 701615 SHARES
20 minute delay
more >
|
